China Optimizes Medical Insurance Policies for COVID-19 Treatment
The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...
RDL
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...
RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study
China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...
NHSA Launches Expert Review for 2025 NRDL Update in China
The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...
Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China
The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...
NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms
The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...
NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals
The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...
NHSA Releases Draft Proposals for NRDL Annual Renewal Process
The National Healthcare Security Administration (NHSA) has formulated and released draft proposals for rules covering...